Received: 11 September 2020
Accepted: 19 January 2021
First Online: 1 February 2021
Ethics approval and consent to participate
: The project was evaluated by the local ethics committee, and it was found that a formal ethical approval was not needed because of the observational design (H-2-2014-FSP53). Despite this, we ensured that all patients gave written informed consent to participate and the study was conducted in accordance with the Declaration of Helsinki.
: No relevant
: Lene Terslev: speaker fee from AbbVie, Janssen, Roche, Novartis, Pfizer, MSD, BMS and GECecilie Heegaard Brahe: noneMikkel Østergaard: research support, consultancy fees and/or speaker fees form Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCBViktoria Fana: noneMads Ammitzbøll Danielsen: noneTorsten Møller: noneSimon Krabbe: research support from AbbVie, MSD and NovartisMerete L Hetland: grants from Bristol-Myers Squibb, AbbVie, Roche and Novartis; grants and personal fees from MSD, Biogen and Pfizer; and personal fees from Eli Lilly, Orion Pharma, CellTrion, Samsung Bioepis and Janssen Biologics B.V.Uffe Møller Døhn: consultancy fees from Eli Lilly, Roche and Novartis; speaker fee from Roche, Novartis